SNS-101 Topline Monotherapy & Combination Dose Escalation Data

June 3, 2024

Presenters:

Dr. Shiraj Sen

Medical Oncologist and Director of Clinical Research, NEXT Oncology-Dallas Principal Investigator for Ph1 trial of SNS-101 Lead author for ASCO poster presentation



John Celebi Chief Executive Officer

Edward van der Horst

Chief Scientific Officer

Ron Weitzman

Chief Medical Officer

Disclaimer

This presentation has been prepared by Sensei Biotherapeutics, Inc. (the "Company," "we," "us") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and the delivery of this presentation at any time shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.


This presentation contains "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 that are based on our management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, expectations regarding the development and potential therapeutic benefits of our product candidates; the expected safety, pharmacokinetic and efficacy profile of our product candidates, including SNS-101; the expected timing of clinical data from our Phase 1/2 clinical trial of SNS-101; the expansion of the Phase 1 clinical trial to include additional patients with specific tumor types; and our belief that our existing cash and cash equivalents will be sufficient to fund our operations at least into the fourth quarter of 2025.

When used in this presentation, the words and phrases "designed to," "may," "believes," "intends," "seeks," "anticipates," "plans," "estimates," "expects," "should," "assumes," "continues," "could," "will," "future" and the negative of these or similar terms and phrases are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as preclinical discovery and development; conduct of clinical trials and related regulatory requirements, including the risk of delay or cessation of any clinical trials of Sensei's product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical trials and early results from the clinical trial of SNS-101, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Sensei's product candidates, including SNS-101: our reliance on third parties over which we may not always have full control: risks regarding the accuracy of our estimates of expenses, capital requirements and needs for additional financing; and other risk and uncertainties that are described in our Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024 and our other Periodic Reports filed with the SEC. Forward-looking statements represent our management's beliefs and assumptions only as of the date of this presentation and include all matters that are not historical facts. Our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forwardlooking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Certain information contained in this presentation relates to, or is based on, studies, publications, surveys and other data obtained from thirdparty sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.



VISTA is a Potent T cell Checkpoint Extensively Expressed on Myeloid Cells




Immunosuppressive function believed to be mediated by PSGL-1 receptor

Upregulated on immune suppressive myeloid-derived suppressor cells (MDSCs) via hypoxia²


Increased expression on tissue infiltrating immune cells upon checkpoint therapy failure³

IS ACTIVATED IN A pH SENSITIVE MANNER



Extensive VISTA expression on off-tumor myeloidlineage cells demands a conditionally active antibody approach

VISTA has inherent pH sensitivity: its extracellular domain is uniquely rich in histidines⁴



T-cell proliferation & activation




1 Wang et al, JEM, 2011 2 Deng et al, Cancer Immunonol Res 2019 3 Gao et al., Nat Med. 2017 4 Johnston et al., Nature 2019

Competitors Previously Developing VISTA Antibodies Challenged by Severe Toxicities & Poor PK From Off-Tumor On-Target Activity

Dose-limiting toxicity Grade 3 CRS-associated encephalopathy

- JNJ-61610588 (CI-8993) was the first anti-VISTA antibody to be studied in clinical trials in 2016 (NCT02671955) ¹
- Transient Cytokine Release Syndrome (CRS) observed in several patients at 0.15 mg/kg
- Transient Grade 3 CRS-associated encephalopathy observed at 0.3 mg/kg, after which Janssen halted the study

Challenging PK profile Non-linear PK, short t_{1/2}





SNS-101 is a pH-sensitive Antibody Selective for VISTA

3.

2-

0

Mean OD450

Selectivity for active VISTA^{pH6} over VISTA^{pH7.4}

Blocks the key receptor regulating VISTA's immunosuppressive activity

0

IC50 = 7nm

-2


log (Conc.) (µM)

SNS-101 potently inhibits the VISTA:PSGL-

1 interaction and all other potential binding

SNS-101 heavy chain

SNS-101 light chain







PSGL-1

-3

partners at pH 6.0 in vitro

Human VISTA

(shown in

green and red)

2.59 Å Resolution

Human VISTA

epitope for SNS-


101

VISTA:SNS-101 co-crystal structure

VISTA's PSGL-1 epitope

demonstrates SNS-101 encompasses

SNS-101 Designed to Bind VISTA at the Tumor but Not in the Periphery





Early Development Plan is in Alignment with Corporate Objectives

Corporate Objectives	Impact on Study Design
 PRIMARY Rapidly confirm conditionally active MOA through: Lack of severe CRS Absence of TMDD Reach doses several folds higher than doses where prior anti-VISTA mAbs experienced DLT 	 Enroll all-comer solid tumor population during dose escalation which included both "hot" and "cold" tumor histologies, allowing for efficient enrollment
 SECONDARY Explore VISTA's role in both "cold" and "hot" tumor settings to allow for efficient enrollment and to explore signs of activity in both settings Identify RP2D 	 Enroll selected patient populations to balance cold/hot tumor ratio Explore more discreet range of doses




SNS-101 Phase 1 Study

Designed to rapidly confirm conditionally active MOA through:

- 1. Lack of severe CRS
- 2. Acceptable PK
- 3. Dosing at pharmacologically relevant levels





* cemi = Libtayo (cemiplimab) 350 mg



RP2D = Recommended Phase 2 Dose MTD = Maximum Tolerated Dose CRC = colorectal cancer NSCLC = non small cell lung cancer H&N = head and neck cancer

Patient Disposition

	Monotherapy	Combination	
	SNS-101 n=16 (%)	SNS-101 + cemi n=18 (%)	
Enrolled	16 (100.0)	18 (100.0)	
Treatment Ongoing	2 (13)	2 (11)	
Discontinued	14 (88)	16 (89)	
Progressive Disease	13	13	
Adverse Event	0	1#	
Withdrew Consent	0	1	
Death Regardless of Causality	1*	0	
Death Related to Study Therapy	0	0	
Clinical Progression	0	1	

* Related to disease progression, not related to SNS-101 (1 mg/kg dose level) # Patient discontinued due to immune mediated AEs of Grade 3 AST and ALT (10 mg/kg + cemi)



Majority of Patients had Tumor Type Typically Unresponsive to PD-1 Monotherapy

	SNS-101 Mono n=16 (%)	SNS-101 Combo n=18 (%)		SNS-101 Mono n=16 (%)	SNS-101 Combo n=18 (%)
Gender, n (%)			Prior lines metastatic therapy		
Male	12 (75)	11 (61)	Median	2	2.5
Female	4 (25)	7 (39)	Min, Max	0,7	1,7
Age, years			Prior PD-1/PDL-1 YES%		
Median	61.5	62	% Yes	8 (50)	4 (22)
Min, Max	35, 79	33, 81	Cancer Type, n (%)		
Race, n (%)					
Asian	1 (6)	1 (6)	Responsive to PD-1 monotherapy (e.g. "hot" tumors)	3 (19)	2 (11)
Black or African American	0	2 (11)	Head and Neck	2	0
Not Reported	1 (6)	1 (6)	Kidney	1	2
White	14 (88)	14 (77)	Typically Unresponsive to PD-1	13 (81)	16 (89)
Ethnicity, n (%)			monotherapy (e.g. "cold" tumors)		
Not Hispanic or Latino	14 (88)	14 (77)	MSS Colon	4	7
Hispanic or Latino	1 (6)	3 (17)	MSS Endometrial	0	1
Not reported	1 (6)	1 (6)	Esophageal	1	0
Baseline ECOG, n (%)			Pancreatic	0	3
0	6 (37)	4 (22)	Sarcoma*	4	2
1	10 (63)	14 (78)	Other**	4	3

~85% of enrolled patients had tumors typically unresponsive to PD-1/PD-L1 therapy



Data as of 30April2024

*Sarcoma: Leiomyosarcoma, Ewing Sarcoma, PEComa, Hemangiopericytoma (mono) and Leiomyosarcoma and Desmoplastic small round cell (combo)

**Other Tumor Types: Small cell lung carcinoma, Gallbladder, Adenocystic carcinoma maxillary sinus, and mediastinal carcinoma (mono) and Ovarian, Duodenal, granulosa cell tumor (germ cell)

SNS-101 Was Well Tolerated as Monotherapy and in Combination with Cemiplimab

- No dose-limiting toxicities observed
- Majority of AEs were Grade 1 or 2
- Two patients experienced Grade 1 CRS, suggesting that CRS is a class effect of VISTA-targeting antibodies

Summary of Adverse Events

	SNS-101 n=16 (%)	SNS-101 + cemi n=18 (%)
At least 1 TEAE	13 (81)	14 (78)
At least 1 SAE	1 (6)	8 (44)
≥Grade 3 TEAE	2 (13)	8 (44)
At least 1 TEAE leading to discontinuation	1* (6)	1 (5)
DLTs	0	0
AESI	1 (6)	5 (28)
Immune-mediated [^]	0	4 (22)
CRS#	1 (6)	1 (6)

*One patient experienced an SAE, Grade 5 bronchial obstruction, that resulted in death; not related to SNS-

101, but to disease progression

#Two patients experienced Grade 1 CRS

^One patient experienced Grade 2 rash maculo-papular at 3 mg/kg + cemi

^One patient experienced Grade 3 Diabetic Ketoacidosis at 3 mg/kg + cemi

[^]Two patients experienced elevated liver enzymes both at 10 mg/kg + cemi (one pt with Grade 3 ALT and

Grade 1 AST and one pt with Grade 3 AST and ALT which resulted in discontinuation from treatment)



Most Frequently Occurring AEs (≥ 2 Overall) Regardless of Causality

Preferred Term	SNS-101 Mono n=16	SNS-101 Combo n=18	Total n=34
Fatigue	0	5	5
Cough	3	1	4
Pleural effusion	1	2	3
Pyrexia	2	1	3
Rash maculopapular	1	2	3
Alanine aminotransferase increased	0	2	2
Anaemia	0	2	2
Aspartate aminotransferase increased	0	2	2
Blood bilirubin increased	0	2	2
Chills	1	1	2
COVID-19	1	1	2
Cytokine release syndrome	1	1	2
Dermatitis acneiform	2	0	2
Hypokalemia	1	1	2
Hypomagnesemia	1	1	2
Infusion related reaction	0	2	2
Lymphocyte count decreased	0	2	2
Nausea	0	2	2
Pruritis	0	2	2

SNS-101 Has Only Been Associated with <u>Mild</u> IRR/CRS-like Adverse Events (Unlike First Generation VISTA Antibodies)

Subject Number	Dose Level	Adverse Event Preferred Term (Event description)	Severity (Grade)	Time of Onset relative to start of Infusion
01-010	SNS-101 15.0 mg/kg	Cytokine Release Syndrome (Chills and fever)	Grade 1	C1D1 ~4 hours postSNS-101 Infusion
01-013	SNS-101 15.0 mg/kg + cemi	Cytokine Release Syndrome (Chills, no fever)	Grade 1	C1D1 ~5 hours post SNS-101 Infusion
01-009	SNS-101 3.0 mg/kg + cemi	Infusion-related reaction (Chills and flushing)	Grade 2	C2D1 At the end of the SNS-101 Infusion
04-015	SNS-101 15.0 mg/kg + cemi	Infusion-related reaction (chest tightness, muscle aches, hypotension) Patient also reported grade 1 itching and flushing about 1 hour after C1D1	Grade 2	C2D1 ~6 minutes after start of SNS- 101 infusion

- All CRS events have been low grade and manageable
- Demonstrates that SNS-101 has the potential to overcome a key hurdle that impeded development of first-generation VISTA mAbs




Pharmacokinetic Data Show Linear Elimination Kinetics with Long Half-Life

- Dose proportional exposure through 5 dose levels of SNS-101 (0.3 to 15.0 mg/kg) .
- Consistent with lack of TMDD and supports Q3W dosing in humans •
- No apparent effect on PK with combination •

BIC

- Some increase with repeat dosing, but no notable accumulation •
- No significant immunogenicity detected in analysis of ADAs





SNS-101

* Cemiplimab administered on Cycle 1 Day 2; co-administration thereafter

SNS-101 + cemiplimab

No Significant Changes in Key Inflammatory Cytokines






sensei

BIO

Dose-dependent Changes in Specific T-cell Populations Indicate Potential SNS-101-Related Pharmacological Effect




SNS-101 Alone or in Combination with Cemiplimab Has Shown Early Signs of Clinical Activity

Monotherapy Dose Escalation

- 16 patients enrolled: 15 patients received both baseline and at least one follow-up scan
- 7 patients achieved stable disease as best overall response
- Patients of interest:
 - One pembrolizumab-resistant HPV+ H&N pt had tumor regression of 17% at a dose level of 15.0 mg/kg; discontinued at Week 12 due to PD
 - One pt with adenocystic carcinoma (maxillary sinus) continues on treatment with SD at 42+ weeks at a dose level of 1.0 mg/kg
 - One pt with leiomyosarcoma (kidney) continues on treatment with SD at 24+ weeks at a dose level of 15.0 mg/kg

Combination Dose Escalation

- 18 patients enrolled: 17 patients received both baseline and at least one follow-up scan.
- Patients of interest:
 - One MSS endometrial pt at 3 mg/kg + cemi had a confirmed PR (59% decrease); ongoing 30+ weeks
 - One MSS colon pt at 3 mg/kg + cemi had tumor regression of 27%; discontinued at Week 18 due to PD
 - One RCC pt at 10 mg/kg + cemi had tumor regression of 18%; discontinued due to immune-mediated toxicity



Subject Number

Two Examples of Patients with MSS Solid Tumors and Objective Tumor Regression

I/O-naïve MSS Endometrial Cancer with PR 3.0 mg/kg SNS-101 + cemiplimab (Patient 01-005)

68 yo female with endometrial carcinoma, dx Dec 2020, ECOG 0

• ER/PR positive, HER negative; PD-1/PD-L1: Not tested

Prior Treatment/Surgery

- Total laparoscopic hysterectomy with bilateral salpingo-oophorectomy, and additional sentinel lymph node dissection, Dec 2020
- Paclitaxel/Carboplatin (adjuvant setting), Feb 2021 to Aug 2021
- Anastrozole (metastatic setting), Aug 2023 to Sep 2023

Adverse Events

- Grade 3 diabetic ketoacidosis 4 days after Cycle 3 infusions, related to SNS-101 and cemiplimab, AESI (immune-mediated) and SAE (hospitalization)
 - Patient recovered and maintained on Insulin and continued study therapy

Tumor Assessments in Solitary Target Lesion

Baseline	6-Week	l 2-Week	l 8-Week	24-Week	30-Week
	SD (-0.6%)	PR (-34%)	(-45%)	PR (-52%)	PR (-59%)

I/O-naïve MSS Colon Cancer 3.0 mg/kg SNS-101 + cemiplimab (Patient 04-010)

62 yo male with colon cancer; dx Jan 2017, ECOG 1

• PD-1/PD-L1: Negative

Prior Treatment/Surgery

 Received 7 prior lines of therapy in the metastatic setting with the last 3 therapies investigational

Adverse Events

- Grade 2 dry skin, related to SNS-101, not related to cemiplimab
- Grade 2 rash maculo-popular, related to SNS-101 and cemiplimab, AESI (immune-mediated), resolved after treatment with prednisone
- Grade 2 pruritis, related to SNS-101 and cemiplimab

Tumor Assessments

- 6-Week Scans: Stable Disease (19% decrease)
- 12-Week Scans: Stable Disease (27% decrease)
- 18-Week Scans: Progressive Disease (23% increase from nadir)


Microsatellite stable (MSS) colon and endometrial tumors are typically unresponsive to PD-1/PD-L1 single agent therapy



SNS-101 ASCO 2024 Summary

SNS-101 is a conditionally active VISTA targeting mAb that has demonstrated promising early clinical data consistent with its mechanism of action, including:


- First VISTA-targeting mAb without dose-limiting CRS at pharmacologically relevant dose levels
- Initial signals of anti-tumor activity in a predominantly "cold" solid tumor patient population



SNS-101 well positioned to be the first VISTA-targeted mAb to test the VISTA IO hypothesis



SNS-101 Next Steps



- Patient enrollment advancing in dose expansion cohorts
- Exploring two dose levels in the combination cohort to further optimize study design for Phase 2
- Expansion tumor types focused on a basket of "hot" tumors and one "cold" tumor, to rebalance between cold/hot given ~85% of patients in dose escalation had "cold" tumor types.
 - Additional tumor types and doses may be considered
 - All patients with "hot" tumors will have received and failed a prior PD-1/PDL-1
- Expansion phase expected to include ~50 to 70 patients
- Cash runway guidance unchanged (Q4 2025)

Initial data from dose expansion expected in Q4 2024



cemiplimab 350 mg
 "Hot" tumors: Responsive to PD-1 monotherapy
 "Cold" tumors: Unresponsive to PD-1 monotherapy

RP2D = Recommended Phase 2 Dose MTD = Maximum Tolerated Dose CRC = colorectal cancer NSCLC = non small cell lung cancer H&N = head and neck cancer



HQ: 1405 Research Blvd, Suite 125, Rockville, MD 20850 / MA: 22 Boston Wharf Rd, 7th floor, Boston, MA 02210

senseibio.com

SNS-101 Duration of Treatment

